Five Below (NASDAQ:FIVE) Releases FY20 Earnings Guidance

Share on StockTwits

Five Below (NASDAQ:FIVE) issued an update on its FY20 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $3.11-3.19 for the period, compared to the Thomson Reuters consensus estimate of $3.14. The company issued revenue guidance of $1.877-1.892 billion, compared to the consensus revenue estimate of $1.89 billion.Five Below also updated its FY 2019
After-Hours guidance to 3.11-3.19 EPS.

Shares of Five Below stock traded up $2.04 during trading on Wednesday, reaching $118.06. The company’s stock had a trading volume of 3,159,145 shares, compared to its average volume of 1,000,913. The business’s 50-day moving average price is $126.06 and its 200-day moving average price is $124.49. The firm has a market cap of $6.89 billion, a PE ratio of 45.94, a P/E/G ratio of 1.68 and a beta of 0.53. Five Below has a 52 week low of $86.57 and a 52 week high of $148.21. The company has a quick ratio of 1.09, a current ratio of 1.98 and a debt-to-equity ratio of 1.08.

FIVE has been the subject of a number of recent research reports. Royal Bank of Canada boosted their target price on shares of Five Below from $126.00 to $130.00 and gave the company an outperform rating in a research report on Thursday, August 29th. UBS Group reduced their target price on shares of Five Below from $132.00 to $124.00 and set a neutral rating for the company in a research report on Tuesday, August 20th. Guggenheim reissued a buy rating and issued a $140.00 target price on shares of Five Below in a research report on Monday, November 25th. BidaskClub cut shares of Five Below from a hold rating to a sell rating in a research report on Saturday. Finally, ValuEngine cut shares of Five Below from a buy rating to a hold rating in a research report on Wednesday, November 20th. Two research analysts have rated the stock with a sell rating, five have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of $137.78.

In related news, Director Thomas Vellios sold 60,000 shares of the business’s stock in a transaction dated Thursday, October 17th. The stock was sold at an average price of $133.31, for a total value of $7,998,600.00. Following the completion of the transaction, the director now owns 604,186 shares of the company’s stock, valued at $80,544,035.66. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 2.50% of the stock is owned by insiders.

Five Below Company Profile

Five Below, Inc operates as a specialty value retailer in the United States. It offers accessories, including novelty socks, sunglasses, jewelry, scarves, gloves, hair accessories, athletic tops and bottoms, and T-shirts, as well as nail polishes, lip glosses, fragrances, and branded cosmetics; and items used to complete and personalize living space, including glitter lamps, posters, frames, fleece blankets, plush items, pillows, candles, incense, lighting, novelty d├ęcor, and related items, as well as provides storage options for the customers room.

See Also: Why do corrections happen?

Earnings History and Estimates for Five Below (NASDAQ:FIVE)

Receive News & Ratings for Five Below Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Below and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

QuickLogic  Downgraded by Zacks Investment Research to Sell
QuickLogic Downgraded by Zacks Investment Research to Sell
Regeneron Pharmaceuticals  Upgraded to “Buy” by BidaskClub
Regeneron Pharmaceuticals Upgraded to “Buy” by BidaskClub
Proofpoint  Raised to “Buy” at BidaskClub
Proofpoint Raised to “Buy” at BidaskClub
Omeros  Upgraded at BidaskClub
Omeros Upgraded at BidaskClub
360 Finance  Rating Increased to Buy at ValuEngine
360 Finance Rating Increased to Buy at ValuEngine
Kiniksa Pharmaceuticals  Downgraded by Zacks Investment Research to “Sell”
Kiniksa Pharmaceuticals Downgraded by Zacks Investment Research to “Sell”


 
© 2006-2020 Zolmax.